Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum

Key facts

Sponsor

Wake Forest University Health Sciences

Principal Investigator

Joseph Jorizzo, MD

Wake Forest University Health Sciences

Intervention

adalimumab(drug)

Eligibility

18 years · All sexes

Timeline

2007 – 2007

Study locations (1)

• Wake Forest University Health Sciences Dermatology, Winston-Salem, North Carolina, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Classic pyoderma gangrenosum

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE3NCT06624670
  A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
  Boehringer Ingelheim
• RECRUITINGPHASE2NCT06563323
  Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)
  Oregon Health and Science University

See all trials for Classic pyoderma gangrenosum →